

For your male and postmenopausal female patients with osteoporosis at high risk for fracture

Your guide to starting patients on TYMLOS

INDICATIONS AND IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE

TYMLOS is indicated for the:

- treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.
- treatment to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.

Please see Important Safety Information on last page and read full Prescribing Information at TYMLOSPI.com.

ONCE YOU HAVE DETERMINED THAT TYMLOS IS THE APPROPRIATE OPTION FOR YOUR PATIENTS

Prescribe TYMLOS using a Specialty Pharmacy (SP):



TYMLOS is available through Specialty Pharmacies. SPs may provide assistance beyond that of a retail pharmacy, such as investigating your patient's health insurance benefits and assisting you with Prior Authorization (PA) requests. Regardless of which SP your office works with, TYMLOS will likely be available. TYMLOS may also be available at an SP that is affiliated with an Integrated Delivery Network.



You can download the TYMLOS Specialty Pharmacy Intake Form for your patient by visiting **tymlosHCPresources.com**.

THE PATH TO TYMLOS IN 4 STEPS



Step 1 Gather relevant patient information for Rx and PA

Record insurance information

Record your patient's Member ID and Group, PCN, and Rx BIN numbers (as available) for their primary medical insurance and prescription drug benefit.* Also verify whether or not your patient has secondary insurance.

Record medical history

- Confirm the following medical history factors, as appropriate. This information will be required to populate a PA form:
 - Diagnosis of osteoporosis
 - BMD T-scores ≤ -2.5 at the lumbar spine, total hip, femoral neck
 - Any history of fragility fracture, including fracture of the spine, hip, shoulder, pelvis, or forearm
 - Risk factors for fracture (e.g., fracture risk assessment tool FRAX®, rheumatoid arthritis, alcohol intake of 4 or more units a day, smoking, high risk for falls, and/or low body mass)
 - Prior treatments and responses (e.g., contraindications, drug interactions, treatment failures, adverse events)

^{*}Some insurance plans include medical and prescription drug benefit information on 1 card; others provide 2 cards.



Ensure you include with prescription:

	Patient	Diagnosis	ICD-10	Codes:
--	---------	-----------	---------------	--------

- M80 Osteoporosis with current pathological fracture
- M81 Osteoporosis without current pathological fracture
- TYMLOS pen, Inject 80 mcg SC daily, 1.56 mL pen
- Needles 31 gauge x 3/16" (5mm)
- Consider including appropriate number of refills[†]

†TYMLOS course of therapy is 18 months



✓ Step 2

Complete and submit the TYMLOS Specialty Pharmacy Intake Form and PA



• Send form to appropriate Specialty Pharmacy (see following pages for Specialty Pharmacy information)



 A Radius Field Reimbursement team member is ready to assist you. Ask your Sales Representative for more information



✓ Step 3 | Appeal a PA denial, if applicable

Not sure what information to include? Visit tymlosHCPresources.com to download a sample Letter of Appeal and sample Letter of Medical Necessity (LMN) to view what types of information are often required. You may also file a Formulary Exception using an LMN.



Some SPs may provide assistance with submitting a Letter of Appeal or LMN



PA approved, TYMLOS approved ✓ Step 4

If the PA is approved, the prescription for TYMLOS can be filled for your patient.



Specialty Pharmacy will ship TYMLOS to patient once the patient agrees to out-of-pocket cost (if applicable)



TYMLOS (abaloparatide) Specialty Pharmacy Network

Below is a list of Specialty Pharmacies (SPs) that are able to dispense TYMLOS. TYMLOS is only available at these SPs and SPs that are affiliated with Integrated Delivery Networks (IDNs). You may send a TYMLOS prescription via e-prescribing or intake FAX. You can download a TYMLOS Specialty Pharmacy Intake Form at tymlosHCPresources.com.

Specialty Pharmacy Name	NPI	eScript Address*	SP Phone*	Intake Fax*
AcariaHealth	1629195045	1311 W. Sam Houston Pkwy, Ste 130, Houston, TX 77043	855-422-2742	877-541-1503
Accredo®	1346208949	1620 Century Center Parkway, Memphis, TN 38134	800-803-2523	888-302-1028
Ardon Health	1962832071	11835 NE Glenn Widing Dr. Portland, OR 97220	855-425-4085	855-425-4096
CVS Specialty™	1134100134	800 Biermann Court, Mount Prospect, IL 60056	800-237-2767	800-323-2445
CenterWell Pharmacy™	1063675684	9843 Windisch Rd, West Chester, OH 45069	800-486-2668	877-405-7940
Lumicera Health Services	1073947636	310 Integrity Dr, Madison, WI 53717	855-847-3554	855-847-3558
Optum® Specialty Pharmacy	1083045140	1050 Patrol Rd, Jeffersonville, IN 47130-7750	855-242-2241	877-342-4596
Polaris Specialty Pharmacy	1053486795	1010 E. Arrow Hwy, Covina, CA 91724	855-797-0857	800-781-3364
Walgreens Specialty Pharmacy	1972560688	130 Enterprise Drive, Pittsburgh, PA 15275	888-782-8443	877-231-8302
Walmart Specialty Pharmacy	1013934413	2354 Commerce Park Dr. Ste 100, Orlando, FL 32837	877-453-4566	866-537-0877

^{*}Current as of 3/2025. Information is subject to change. Please verify contact information and ship-to locations with the SP.

Prepare your patients to receive 3 important calls from their SP:

- Welcome call
- 2 Prescription delivery call
- 3 Refill reminder




Payer Preferred or Mandated Specialty Pharmacies

IMPORTANT NOTE: Some payers may mandate or prefer a specific Specialty Pharmacy (SP) for TYMLOS, although there are exceptions and carve outs. For verification of benefits, contact the payer directly. For additional information or resources, visit tymlosHCPresources.com.

Specialty Pharmacies by Payer							
Payer	Specialty Pharmacy	SP Phone*	Intake FAX*				
Aetna, Anthem Blue Cross Blue Shield plans, CVS Caremark®, and FEP	CVS Specialty™	800-237-2767	800-323-2445				
Cigna, Express Scripts, Prime Therapeutics, TRICARE, Envision Rx, Magellan, Medimpact (Elixir), and participating Blue Cross Blue Shield plans	Accredo®	800-803-2523	888-302-1028				
Humana®	CenterWell	800-486-2668	877-405-7940				
Moda Health	Ardon Health	855-425-4085	855-425-4096				
Navitus, Wellfirst, Costco, Epiphany Rx	Lumicera Health Services	855-847-3554	855-847-3558				
UnitedHealthcare, OptumRx	Optum® Specialty Pharmacy	855-242-2241	877-342-4596				
Ambetter, Centene, Wellcare	AcariaHealth	855-422-2742	877-541-1503				

^{*}Current as of 3/2025. Information is subject to change. Please verify contact information with the SP.




Eligible, commercially insured patients can pay as little as \$0 a month for their TYMLOS prescription for a 30-DAY SUPPLY.*

*This offer is not valid for patients using Medicare, Medicaid, or other governmentfunded programs to pay for their medication. See back of Savings Card for all eligibility requirements, rules, and restrictions. Savings Card is available for patients to download at TYMLOS.com. Limited to one offer per person.



Please see Important Safety Information on last page and read full Prescribing Information at TYMLOSPI.com.



1-on-1 help for patients

Helps patients with a prescription understand how to use the pen and self-inject and **supports** them as they **start and stay** on **TYMLOS**, as directed by you.

Visit <u>tymlossignup.com</u> or call 1-855-730-8591, Monday–Friday, 8 AM-7 PM ET.



IMPORTANT SAFETY INFORMATION

Contraindications: TYMLOS is contraindicated in patients with a history of systemic hypersensitivity to abaloparatide or to any component of the product formulation. Reactions have included anaphylaxis, dyspnea, and urticaria.

Risk of Osteosarcoma: It is unknown whether TYMLOS will cause osteosarcoma in humans. Osteosarcoma has been reported in patients treated with a PTH-analog in the post marketing setting; however, an increased risk of osteosarcoma has not been observed in observational studies in humans. There are limited data assessing the risk of osteosarcoma beyond 2 years of TYMLOS use. Avoid use of TYMLOS for patients at an increased baseline risk for osteosarcoma including patients with open epiphysis (pediatric and young adult patients); metabolic bone diseases other than osteoporosis, including Paget's disease of the bone; bone metastases or a history of skeletal malignancies; prior external beam or implant radiation therapy involving the skeleton; or hereditary disorders predisposing to osteosarcoma.

Orthostatic Hypotension: Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia, or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.

Hypercalcemia: TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.

Hypercalciuria and Urolithiasis: TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.

Pregnancy and Lactation: TYMLOS is not indicated for use in females of reproductive potential.

Adverse Reactions:

- The most common adverse reactions (incidence ≥2%) reported with TYMLOS in postmenopausal women with osteoporosis are hypercalciuria (11%), dizziness (10%), nausea (8%), headache (8%), palpitations (5%), fatigue (3%), upper abdominal pain (3%), and vertigo (2%).
- The most common adverse reactions (incidence ≥2%) reported with TYMLOS in men with osteoporosis are injection site erythema (13%), dizziness (9%), arthralgia (7%), injection site swelling (7%), injection site pain (6%), contusion (3%), abdominal distention (3%), diarrhea (3%), nausea (3%), abdominal pain (2%), and bone pain (2%).

Please read full Prescribing Information at <u>TYMLOSPI.com</u>.



(abaloparatide) injection 30-day prefilled pen | 80 mcg daily